|
1）Ishibashi Y, Onuma Y, Muramatsu T, et al. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. EuroIntervention. 2014; 10: 449-57
|
|
|
|
2）Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: The ABSORB cohort A trial. JACC Cardiovasc Interv. 2013; 6: 999-1009
|
|
|
|
|
|
3）Gomez-Lara J, Brugaletta S, Diletti R, et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J. 2011; 32: 294-304
|
|
|
|
|
|
4）Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: Six-month clinical and imaging outcomes. Circulation. 2010; 122: 2301-12
|
|
|
|
|
|
5）Abizaid A, Ribamar Costa J Jr, Bartorelli AL, et al. The ABSORB EXTEND study: Preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention. 2015; 10: 1396-401
|
|
|
|
|
|
6）De Ribamar Costa J Jr, Abizaid A, Bartorelli AL, et al. Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold. EuroIntervention. 2015; 11: 141-8
|
|
|
|
|
|
7）Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015; 385: 43-54
|
|
|
|
|
|
8）Kocka V, Maly M, Tousek P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: A prospective multicentre study ‘Prague 19’. Eur Heart J. 2014; 35: 787-94
|
|
|
|
|
|
9）Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: The BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv. 2015; 8: 189-97
|
|
|
|
|
|
10）Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. 2012; 380: 1482-90
|
|
|
|
|
|
11）Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015; 10: 1144-53
|
|
|
|
|
|
12）Wohrle J, Naber C, Schmitz T, et al. Beyond the early stages: Insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention. 2015; 11: 149-56
|
|
|
|
|
|
13）Diletti R, Farooq V, Girasis C, et al. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: Does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart. 2013; 99: 98-105
|
|
|
|
|
|
14）Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010; 362: 1663-74
|
|
|
|
|
|
15）Simsek C, Magro M, Onuma Y, et al. Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: One-month results of the Bioresorbable vascular Scaffold Evaluated at Rotterdam Cardiology Hospitals (B-SEARCH). EuroIntervention. 2014; 10: 236-40
|
|
|
|
|
|
16）Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. EuroIntervention. 2006; 2: 286-94
|
|
|
|
|